Unveiling the Race for a Life-Saving Nipah Virus Vaccine

Описание: Nipah virus, a deadly pathogen, has no approved treatments. CEPI is leading the charge with a $150 million portfolio. We speak to Dr. K Zaman, leading the world's first Phase II Nipah vaccine trial in Bangladesh, and CEPI's Rick Jarman. Discover how CEPI is preparing for this lethal virus.
Fruit juice, a popular drink in Bangladesh, can carry the Nipah virus from bats. This simple drink can be fatal, with a 75% death rate. Scientists are developing a vaccine to protect against this threat.
The University of Oxford and CEPI's ChAdOx vaccine platform have developed a potential vaccine, now in mid-stage trials. Dr. Zaman hopes this trial will save lives in Bangladesh and beyond.
Nipah's natural hosts, fruit bats, range across regions with over 2 billion people. As human activity encroaches, the risk of infection grows. CEPI's partnership with the University of Oxford and Serum Institute of India aims to create a reserve of 100,000 vaccine doses for emergency use.
CEPI's Nipah program lead, Rick Jarman, emphasizes the importance of this investigational reserve and the potential for emergency trials. He estimates a Nipah vaccine within 5 years.
Vaccines are crucial, but CEPI is also funding a Nipah monoclonal antibody (mAb) for immediate protection. The non-profit ServareGMP leads the development of MBP1F5, set to begin trials in 2026.
Together, vaccines and mAbs offer a powerful shield. Investing in novel technologies increases the chances of success and prepares for a potential Disease X from the paramyxovirus family.
CEPI's 100 Days Mission aims to accelerate vaccine development, and these preparedness efforts could stop future Nipah outbreaks and reduce the threat of other paramyxoviruses.